FDA Green Lights AstraZeneca, Merck's Lynparza for Metastatic Breast Cancer Post author:Sam Post published:January 11, 2018 Post category:BioPharma Lynparza is the first and only PARP inhibitor approved for use beyond ovarian cancer. Source: BioSpace You Might Also Like Turns Out Editas Medicine's R&D Deal With Allergan Could be Worth $1 Billion March 22, 2017 AntriaBio Announces $13 Million Close Of Private Placement Transaction And Plan To Dose First Patient With AB101 This Month July 17, 2017 BrainStorm Cell To Announce Third Quarter Financial Results And Provide Corporate Updates On Tuesday, October 17 October 3, 2017
AntriaBio Announces $13 Million Close Of Private Placement Transaction And Plan To Dose First Patient With AB101 This Month July 17, 2017
BrainStorm Cell To Announce Third Quarter Financial Results And Provide Corporate Updates On Tuesday, October 17 October 3, 2017
